Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Unilife Corp | d821565d8k.htm |
| EX-99.1 - EX-99.1 - Unilife Corp | d821565dex991.htm |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
November 13, 2014
Annual General Meeting
Fiscal Year 2014
Exhibit 99.2 |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
November 13, 2014
This
presentation contains forward looking statements under the safe harbor provisions
of the US securities laws. These forward-looking statements are based on
management’s beliefs and assumptions and on information currently
available to our management. Our management believes that these
forward-looking statements are reasonable as and when made. However you
should not place undue reliance on any such forward looking
statements
as
these
are
subject
to
risks
and
uncertainties.
Please
refer
to
our
press releases and our SEC filings for more information regarding the use of forward
looking statements.
Cautionary Note Regarding Forward-Looking Statements
|
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
Welcome.
Mr. Alan Shortall.
Chairman and CEO |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
Introducing our Board of Directors
•
In Attendance
Jim Bosnjak OAM
Mary Kate Wold, J.D.
John Lund, CPA
William Galle
Deputy Chairman
Director since 2002
Chair of the
Compensation
Committee
Non-Executive
Director since 2010
Chair of Strategic
Partnerships
Committee
Non-Executive
Director since 2009
Chair of Audit
Committee
Non-Executive Director
since 2008
Chair of the Nominating
and Corporate
Governance Committee |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
Introducing our Board of Directors
•
Apologies
Jeff Carter MApp. BFin
Non-Executive Director since
2006
Based in Australia |
 Confidential-Unilife Corporation
Agenda
1.
Confirmation of Quorum
2.
Resolutions
3.
Presentation from the CEO
4.
Questions
5.
Confirmation of Results
6.
Other Business |
 Resolutions
1.00
Election of Directors
1.01
Elect Slavko James Joseph Bosnjak
1.02
Elect Jeff Carter
1.03
Elect William Galle
1.04
Elect John Lund
1.05
Elect Mary Katherine Wold
1.06
Elect Alan Shortall
2.00
Ratification of Auditor
3.00
Advisory Vote on Executive Compensation
4.00
Ratify Placement of Securities (Cantor)
5.00
Amendment to 2009 Stock Incentive Plan
6.00
Equity Grant
Confidential-Unilife Corporation |
 Confidential-Unilife Corporation
Confirmation of Quorum
•
Unilife’s quorum
requirement is one-third of outstanding shares being represented either
in person or by proxy •
At least 55.70% of the total outstanding shares entitled to
vote have been received and are represented by person
or proxy |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
Business Update |
 •
Customer-centric
•
Market-leading
product portfolio
•
High-caliber team
•
Deep technical
capabilities
•
Strong partners
•
Execution with speed
A Preferred Partner Serving Customer Needs
Confidential-Unilife Corporation |
 Confidential-Unilife Corporation
Value
Capitalizing on Converging Market Needs
Patients
Pharmaceutical
companies
Healthcare
providers |
 Confidential-Unilife Corporation
Our Business Model
•
Business to business (attractive operating margins)
•
Multiple shots on goal per customer
•
Long-term supply agreements
•
Predictable, recurring revenue
•
New agreements provide incremental revenue and growth |
 Confidential-Unilife Corporation
Our Commercial Supply Agreements. |
 Our
Commercial Pipeline 15 active
programs
A leading indicator of
the future supply
agreements
Confidential-Unilife Corporation |
 Confidential-Unilife Corporation
A strategic global alliance
Scaling up to Meet Accelerating Demand |
 Building Long-Term Shareholder Value
Confidential-Unilife Corporation |
 Confidential-Unilife Corporation
Building Value. Maximizing Revenue.
•
Continuing to invest in business opportunities that generate
substantial incremental revenue, and maximize value
•
Going cash flow positive is a question of when we choose to do so
•
Continuing to ramp up over the next two years and go
commercial with a growing number of injectable therapies
•
Targeting capacity for 400MM prefilled syringes and 10-15MM
wearable injectors plus scale-up for other products in our portfolio
•
Much of this demand is reserved and pre-sold
•
Alliance with Flextronics supports rapid scale-up to meet customer
demand, reducing capital expenditure expenses and delivering a
favorable and meaningful cash flow benefit on our cash flows.
•
We will continue to invest in business opportunities that will
maximize shareholder value. |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
Annual General Meeting of Stockholders
November 14, 2014
Consider and Vote for Matters set forth in Proxy Statement
|
 Confidential-Unilife Corporation
Election of Directors
Item 1. |
 Confidential-Unilife Corporation
For
Withheld
Item 1.1 Jim Bosnjak
41,718,199
96.4%
1,559,173
3.6%
Item 1.2 Jeff Carter
40,696,315
94.04%
2,581,057
5.96%
Item 1.3 William Galle
41,879,595
96.77%
1,397,777
3.23%
Item 1.4 John Lund
42,342,898
97.84%
934,474
2.16%
Item 1.5 Mary Kate Wold
42,603,519
98.44%
673,853
1.56%
Item 1.6 Alan Shortall
40,896,391
94.50%
2,380,981
5.50%
Election of Directors
Item 1. |
 Confidential-Unilife Corporation
Item 2.
Ratification of the appointment of KPMG LLP as
the Corporation’s independent registered public
accounting firm for Fiscal Year 2015 |
 Confidential-Unilife Corporation
Item 2.
Ratification of the appointment of KPMG LLP as
the Corporation’s independent registered public
accounting firm for Fiscal Year 2015
For
Against
Abstain
Item 2.
60,485,400 (99.48%)
210,006 (0.35%)
100,479 (0.17%) |
 Confidential-Unilife Corporation
To consider and act on an advisory vote regarding
the approval and compensation paid to certain
executive officers
Item 3. |
 Confidential-Unilife Corporation
To consider and act on an advisory vote regarding
the approval and compensation paid to certain
executive officers
For
Against
Abstain
Item 2.
34,117,944 (78.84%)
8,356,877 (19.31%)
802,551 (1.85%)
Item 3. |
 Confidential-Unilife Corporation
Item 4.
To ratify the issuance and sale of 7,308,800 shares of
common stock under the controlled equity offering
sales agreement entered into with Cantor Fitzgerald. |
 Confidential-Unilife Corporation
Item 4.
To ratify the issuance and sale of 7,308,800 shares of
common stock under the controlled equity offering
sales agreement entered into with Cantor Fitzgerald.
For
Against
Abstain
Item 4.
40,868,342 (94.44%)
1,909,643 (4.41%)
499,387 (1.15%) |
 Confidential-Unilife Corporation
Item 5.
To approve the issue and transfer of securities under
the 2009 Stock Incentive Plan and approval of the
2009 Stock Incentive Plan as amended. |
 Confidential-Unilife Corporation
Item 5.
To approve the issue and transfer of securities under
the 2009 Stock Incentive Plan and approval of the
2009 Stock Incentive Plan as amended.
For
Against
Abstain
Item 5.
34,584,320 (79.92%)
8,289,250 (19.15%)
403,802 (0.93%) |
 Confidential-Unilife Corporation
Item 6.
To ratify the issue of up to 4,000,000 shares of
restricted stock to Alan Shortall. |
 Confidential-Unilife Corporation
Item 6.
To ratify the issue of up to 4,000,000 shares of
restricted stock to Alan Shortall.
For
Against
Abstain
Item 6.
32,693,354 (75.54%)
10,027,717 (23.17%)
556,301 (1.29%) |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
Final Comments |
 Confidential-Unilife Corporation
Confidential-Unilife Corporation
Close of Meeting |